louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06112561: Cardiac Index, SVR/SVRI During Weaning From ECC- Data Obtained From Femoral and Radial Artery Transducer
Official title: Fluctuation and Realbility of Cardiac Index and SVR/SVRI During Weaning From ECC Regarding Values Obtained From Femoral and Radial Artery Acumen IQ Sensor
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Aortic Valve Disease
Mitral Valve Disease
Keywords: cardiac output
cardiac index
systemic vascular resistance
Lead sponsor: George Papanicolaou Hospital
Sponsor class: OTHER
First posted: 2023-11-01
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Swan Ganz catheter-Edwards Lifesciences obtains values of cardiac output/index and systemic vascular resistance/index using the mean artery pressure of either radial or femoral artery.

During weaning from extracorporeal circulation, arterial waveform-derived cardiac output measurements from radial cannulation site is not reliable as compared with measurements obtained from femoral cannulation site.

Detailed description: 50 consecutive cardiac surgical patients undergoing on-pump primary coronary artery bypass, valve replacement or combined surgery are included in the study. Cardiac output is measured sequentially by the arterial pressure waveform analysis method from radial and femoral arterial sites

Eligibility criteria: Inclusion Criteria: Coronary artery disease , aortic valve stenosis, aortic valve regurgitation, mitral valve stenosis, mitral valve regurgitation,

Exclusion Criteria: none

Primary outcomes:
measure: Cardiac output
timeFrame: 5 minutes after weaning from extracorporeal circulation (ECC)
measure: Prediction of hypotension episode (HPI)
timeFrame: 5 minutes after weaning from ECC
measure: Systemic Vascular resistance (SVR)
timeFrame: 5 minutes after weaning from ECC
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: George PAPANIKOLAOU G.H.
name: Olga Ananiadou, MD,PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00259961: Clinical Outcome of Laparoscopic Versus Open Nissen Fundoplication in Children: 3-Year Follow-up Study of Randomized Controlled Trial.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastro -Oesophagal Reflux
Lead sponsor: Institute of Child Health
Sponsor class: OTHER
First posted: 2005-12-01
Sex: ALL
Minimum age (years): 3
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: Long-term results following laparoscopic and open Nissen fundoplication for gastro-oesophageal reflux will be objectively assessed in a selected population of patients already included in a randomized controlled trial comparing the two different techniques. The presence of postoperative symptoms will be evaluated by an independent clinician using an objective questionnaire. The recurrence of gastro-oesophageal reflux will be studied by 24-hours pH study. Furthermore the presence of gastric motility disorders will be studied by electrogastrography and 13C-octanoic acid breath test.


Eligibility criteria: Inclusion Criteria: All patients with gastro - oesophagal reflux -

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Great Ormond Street Hospital
Study officials:
affiliation: Great Ormond Street Hospital
name: Pierro Agostino, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pacilli M, Eaton S, McHoney M, Kiely EM, Drake DP, Curry JI, Lindley KJ, Pierro A. Four year follow-up of a randomised controlled trial comparing open and laparoscopic Nissen fundoplication in children. Arch Dis Child. 2014 Jun;99(6):516-21. doi: 10.1136/archdischild-2013-304279. Epub 2014 Feb 14.
Clinical trial NCT03171961: Effectiveness of Online Visit Compared With In-person Clinic Visit on Weight Loss
Official title: Effectiveness of Online Visit Compared With In-person Clinic Visit on Weight Loss in Overweight and Obese Women, a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Overweight
Keywords: weight loss
Diet
online visit
clinic visit
Lead sponsor: Novindiet Clinic
Sponsor class: OTHER
Collaborators: name: University of Nottingham
name: Tehran University of Medical Sciences
First posted: 2017-05-31
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Online visit and online counseling via telemedicine technology is a new service for obese people who wish to lose weight but because of their active lifestyle and time limitation cannot come to clinic. The purpose of this study was to examine the efficacy this technology-based intervention on weight loss in obese and overweight female adults.


Eligibility criteria: Inclusion Criteria:

* Must be female
* Must be 18-45 years of age.
* Must have Body mass index (BMI) between 27-35 kg/ m².
* Must be able to have moderate exercise.
* Must be interested to have weight loss.
* Have access to the internet via broad- band ADSL or Mobile 4G

Exclusion Criteria:

* Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months.
* Taking medications that could affect metabolism or change body weight.
* Report heart problems, chest pain, and cancer within the last five years.
* Smoking
* Menopause
* Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Primary outcomes:
measure: weight
timeFrame: 24 Weeks
Secondary outcomes:
measure: Waist circumference
timeFrame: 24 Weeks
measure: Fasting blood glucose
timeFrame: 24 Weeks
measure: Fasting insulin level
timeFrame: 24 Weeks
measure: HbA1c
timeFrame: 24 Weeks
measure: HOMA-IR
timeFrame: 24 Weeks
measure: lipid profiles
timeFrame: 24 Weeks
measure: liver function tests
timeFrame: 24 Weeks
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: NovinDiet Clinic
city: Tehrān
country: Iran, Islamic Republic of
facility: NovinDiet Clinic
Study officials:
References:
Clinical trial NCT03069261: Intraoperative Indocyanine Green Laser Angiography; Postoperative Outcomes for Autologous Tissue Flaps
Official title: Intraoperative Indocyanine Green Laser (ICG) Angiography; Evaluation of Postoperative Outcomes for Breast Reconstruction With Autologous Tissue Flaps
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Breast reconstruction
Autologous tissue flaps
Indocyanine green angiography
Breast cancer
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2017-03-03
Enrollment: 171
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent immediate or delayed, pedicle autologous flap breast reconstruction between 2012 and 2016 were enrolled in the study.

Brief summary: The purpose of this study is to identify and compare complication rates between autologous breast reconstruction techniques with and without the inclusion on intraoperative indocyanine green (ICG) angiography.

Detailed description: ICG-angiography is a real-time visualization of tissue perfusion using intravenous fluorescence. It allows the surgeon a tool for intraoperatively assessment of tissue perfusion of the autologous flap, providing a basis for trimming of hypo perfused areas. The study evaluates the effect of inclusion of this technique by examine postoperative outcomes retrospectively. This is done by differentiation between major and minor complications to evaluate the greatest gains of the intervention.

Eligibility criteria: Inclusion Criteria:

* Eligible patients over the age of 18 years
* Deemed suitable for breast reconstruction with the latissimus dorsi (LD) myocutaneous flap, muscle sparring LD flap or transverse rectus abdominal muscle (TRAM) flap

Exclusion Criteria:

* Patients with recurrence of breast cancer
* Smoking 4 weeks prior of operation
* Not able to read and understand Danish

Primary outcomes:
measure: Major complications
timeFrame: Measured at 6 months followup.
Secondary outcomes:
measure: Minor complications
timeFrame: Measured from day 0 with 6 months followup
measure: Timing of reconstruction
timeFrame: Measured from day 0 with 6 months followup
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04187261: Audit of Hip Fractures Surgically Managed
Official title: Hip Fractures Surgical Management and Complications: Retrospective Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hip Fractures
Lead sponsor: Aga Khan University
Sponsor class: OTHER
First posted: 2019-12-05
Enrollment: 2000
Sex: ALL
Minimum age (years): 1
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: mostly elderly with hi fractures. However we included young patients as well.

Brief summary: Investigators are reviewing the the charts and medical records of participants who were operated at our institute from 2010 onward for hip fractures. Checking their outcomes (Postoperative complications, length of hospital stay and mortality) and studying their background characteristics and potential associated factors.

Detailed description: This retrospective study is a cohort with multiple exposures and groups. From this nested case control will be analysed as well.

Eligibility criteria: Inclusion Criteria:

* All patients, regardless of gender, commodities and age
* Hip fractures which were managed surgically.
* operated at our institute.

Exclusion Criteria:

* Participants with incomplete data or missing information in either the primary exposure or the outcome of interest.
* Participants with pathological fracture, open fractures, poly-trauma or revision surgeries.

Primary outcomes:
measure: postoperative complications
timeFrame: 30 days postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Aga Khan University
state: Sindh
Study officials:
affiliation: Aga Khan Univeristy
name: Obada Hasan, FCPS, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06511661: Prognostic Significance of the Uncertain Resection in NSCLC
Official title: Prognostic Significance of the Uncertain Resection Based on the Extent of Nodal Dissection for Non-small Cell Lung Cancer: A Propensity Score Matching Retrospective Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Non Small Cell Lung Cancer
Residual; State
Keywords: Non-small cell lung cancer
Lymphadenectomy
R stage
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 3783
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The data of included patients is extracted from the Hospital Information System of Sun Yat-sen University Cancer Center from 2001 to 2024.

Brief summary: The concept of residual tumor classification proposed by the Union for International Cancer Control (UICC) was used to assess the completeness of surgical resection, and non-small cell lung cancer (NSCLC) patients with incomplete resection were more likely to occur recurrence, leading to significantly poor survival. But this R classification only refers to the surgical margin and neglects other factors associated with surgical quality, such as the extent of lymph node dissection (LND). Therefore, the International Association for the Study of Lung Cancer (IASLC) proposed the definition of uncertain resection \[R(un)\], which includes the suboptimal extent of LND. However, the clinical significance of R(un) is still controversial. On the one hand, some researches demonstrated that R(un) had definite prognostic significance, with R(un) survival stratifying between R0 and R1. On the other hand, some studies indicated that in early-stage NSCLC, the suboptimal extent of LND had no impact on survival, and the concept of R(un) might be insignificant in these patients. Even in those studies supporting the prognostic significance of R(un), which kind of patients is suitable for R(un) was still unclear. Thus, the investigators explore the impact of the R(un) on the long-term survival of patients with NSCLC using a large cohort in China, to identify those patients who could really benefit from the LND required by the R0 classification proposed by IASLC.


Eligibility criteria: Inclusion Criteria:

1. Primary non-small cell lung cancer
2. With pulmonary resection

Exclusion Criteria:

1. Sublobar resection
2. R1/R2
3. Positive highest mediastinal lymph nodes
4. Operative death

Primary outcomes:
measure: 5-year disease-free survival
timeFrame: 5 years after surgery
measure: 5-year overall survival
timeFrame: 5 years after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Mu-Zi Yang, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02134561: Assessment of the Psychological, Cognitive and Social Resources of Applicants for Huntington's Disease and Presymptomatic Genetic Testing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Presymptomatic Huntington Disease
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2014-05-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to assess the psychological, cognitive and social resources of applicants for Huntington's Disease and Presymptomatic Testing.


Eligibility criteria: Inclusion Criteria:

* Applicants for Huntington's Disease and Presymptomatic Testing
* Aged 18 years and above
* Huntington disease family member
* Subject gave its written consent

Exclusion Criteria:

* No national health insurance affiliation
* Being under guardianship
* Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body, Renal failure, hypersensitivity of Gadolinium) or refusing MRI.
* Patient with movement disorder

Primary outcomes:
measure: Change from baseline total score of the psychological Unified Huntington's Disease Rating Scale at 2 years
timeFrame: 3 months before diagnostic (baseline) ; 2 years after diagnostic,
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: University Hospital of Angers
state: Pays De La Loire
Study officials:
References:
Clinical trial NCT01679561: Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial
Official title: Phase 4 Study of the Efficacy of Intralipid Treatment in Patients With Recurrent Implantation Failure and Miscarriages With High Peripheral and Uterine Natural Killer Cells
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Pregnancy Complicated by Low Implantation
Keywords: implantation failure
recurrent abortion
intralipid
Lead sponsor: Woman's Health University Hospital, Egypt
Sponsor class: OTHER
First posted: 2012-09-06
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Both organ-specific and systemic autoimmunity are associated with an increased prevalence of recurrent miscarriage and reproductive failure, rendering the role of the maternal immunological system in fertility a key concept. It is believed by some that central to this theme is the maternal cytokine profile, with particularly T-helper (Th) cells. Immune modulating therapies have therefore been mooted as potential therapeutic strategies. Recent reports of high pregnancy rates achievable in women with RIF have added fuel to the debate regarding the effectiveness of intralipids in modulating the immune system.

Detailed description: The investigators would like to assess if that intralipids therapy is an effective treatment for women undergoing repeated failed assisted reproduction cycles and recurrent miscarriages against traditional methods in randomised clinical trial (RCT).

Eligibility criteria: Inclusion Criteria:

1. Recurrent unexplained failed IVF, ICSI.
2. Recurrent unexplained miscarriages.
3. High level of peripheral and uterine NK.

Exclusion Criteria:

1. Age above forty years old.
2. Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies \[IgG or IgM\]); other recognised thrombophilic conditions (testing according to usual clinic practice).
3. Intrauterine abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram, or hysteroscopy).
4. Fibroids distorting uterine cavity.
5. Abnormal parental karyotype.
6. Other identifiable causes of recurrent miscarriages (tests initiated only if clinically indicated) e.g., diabetes, thyroid disease and systemic lupus erythematosus (SLE).

Primary outcomes:
measure: The effectiveness of intralipid on normalization of nk level and rate of clinical pregnancy .
timeFrame: 2 ys
Secondary outcomes:
measure: the rate of continuation of pregnancy beyond 12 weeks of pregnancy,the adverse effects related to the drug.
timeFrame: 2 ys
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Women's Health Hospital
Study officials:
affiliation: Faculty of medicine,Assiut university,Egypt
name: Alaa M Ismail, M D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02668861: Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels
Official title: Influence of Oral Vitamin D3 on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis and Lower Vitamin D Levels
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Lead sponsor: The First Affiliated Hospital of Shanxi Medical University
Sponsor class: OTHER
First posted: 2016-01-29
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to test the clinical efficacy of oral Vitamin D3 on Wound Healing in patients with Chronic Rhinosinusitis With Nasal Polyposis and Lower Vitamin D Levels After Endonasal Endoscopic Sinus Surgery


Eligibility criteria: Inclusion Criteria:

* 1. Clinical diagnosis of Chronic Rhinosinusitis with nasal polyps 2. Be 18-60 years old of Chinese people and of either sex，the Han nationality 3. Vitamin D level of less than 30 ng/ml

Exclusion Criteria:

* 1. Women must not be pregnant, breast feeding 2. Chronic oral corticosteroid therapy 3. History of physician-diagnosed nephrolithiasis 4. Chronic diseases（ diabetes，Hypertension，renal insufficiency, severe liver disease） 5.prior surgeries of the paranasal sinuses 6. With an upper respiratory tract infection within 4 weeks of entering the study

Primary outcomes:
measure: VAS evaluation of usual symptoms in patients with CRSwNP
timeFrame: at 8 weeks after first drug intake
measure: Questionnaire：SNOT-20 evaluates the quality of Life
timeFrame: at 8 weeks after first drug intake
measure: Change of Lund-Kennedy scores
timeFrame: at 8 weeks after first drug intake
Secondary outcomes:
measure: Inflammatory mediators in serum
timeFrame: 8 weeks
measure: Histologic analysis of nasal mucosa
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Taiyuan
country: China
facility: The First Hospital of Shanxi Medical University
state: Shanxi
Study officials:
References:
Clinical trial NCT00721461: A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)
Official title: Probe Study of the Tolerability of an Investigational Electroporation Device, MedPulser (Trademark) DNA Delivery System (DDS) in Healthy Adults 18 to 35 Years of Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Assess
Tolerability
MedPulser DDS device
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
Collaborators: name: University of California, San Diego
name: Inovio Pharmaceuticals
First posted: 2008-07-24
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: A study to evaluate the tolerability of electrostimulation applications with an investigational device known as the MedPulser DDS.


Eligibility criteria: Inclusion Criteria:

* Must be between the ages of 18 and 35
* Woman who are able to become pregnant must use an acceptable form of birth control

Exclusion Criteria:

* You are breast feeding
* You have taken any type of pain reliever within 12 hours of electrostimulation
* You have participated in another clinical study within 4 weeks of starting this study or plan to participate in another clinical study while participating in this study
* You have muscle atrophy, weakness or neuromuscular disorder

Primary outcomes:
measure: Assess the tolerability of the MedPulser DDS device.
timeFrame: Severity of pain will be measured at time of treatment and 1, 5, 10, and 20 minutes and 24 hours after electrostimulation.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References: